background c57bl 6 Search Results


90
Jackson Laboratory male fgf21ko mice with c57 bl/6 j background
FGF21 deletion accelerated and aggravated diabetes-induced aortic thickening. At indicated time points after diabetes onset, histological change of aorta was evaluated by H&E staining ( a ) and aorta thickness was measured using Image Pro Plus 6.0 software ( b ). Data are presented as means ± SD, n ≥ 5 for each group. * p < 0.05 vs WT Ctrl group; # p < 0.05 vs <t>FGF21KO</t> Ctrl group; & p < 0.05 vs WT DM group. Bar = 50 μm. Ctrl: control; DM: diabetes mellitus; WT: wild type; FGF21KO: FGF21 knockout; m: month(s)
Male Fgf21ko Mice With C57 Bl/6 J Background, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/background+c57bl+6/male+fgf21ko+mice+with+c57+bl+6+j+background/pmc04484638-35-5-35
Average 90 stars, based on 1 article reviews
male fgf21ko mice with c57 bl/6 j background - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Jackson Laboratory pd-1−/− mice on c57/bl/6 background
FGF21 deletion accelerated and aggravated diabetes-induced aortic thickening. At indicated time points after diabetes onset, histological change of aorta was evaluated by H&E staining ( a ) and aorta thickness was measured using Image Pro Plus 6.0 software ( b ). Data are presented as means ± SD, n ≥ 5 for each group. * p < 0.05 vs WT Ctrl group; # p < 0.05 vs <t>FGF21KO</t> Ctrl group; & p < 0.05 vs WT DM group. Bar = 50 μm. Ctrl: control; DM: diabetes mellitus; WT: wild type; FGF21KO: FGF21 knockout; m: month(s)
Pd 1−/− Mice On C57/Bl/6 Background, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/background+c57bl+6/pd+1++++mice+on+c57+bl+6+background/pm39441651-66-20-24
Average 90 stars, based on 1 article reviews
pd-1−/− mice on c57/bl/6 background - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Shanghai Model Organisms Center slc16a1 flox/flox mice
( A ) Schematic showing metabolic pathways of glucose and lactate between blood and skeletal muscle in mice after infusion of [U- 13 C] glucose or [U- 13 C] lactate. ( B ) Normalized labeling from 2.5-hour [U- 13 C] glucose or [U- 13 C] lactate infusion of glycolytic products in QUA, TA, GAS, and SOL. n = 2 to 3. ( C ) Schematic of TCA intermediates, for example, malate, produced from [U- 13 C] glucose or [U- 13 C] lactate by jugular vein catheterizing in tissues. ( D ) Direct sources of muscle lactate and malate from circulatory labeled glucose and lactate. n = 2 to 3. ( E ) Immunofluorescence staining of MCT1 (blue) with muscle fiber markers for type IIA (green, recognized by anti-MyHC IIA), type IIB (purple, recognized by anti-MyHC IIB), and type IIX (unstained). Scale bars, 100 μm. ( F ) Scheme showing the strategy of generating mouse with <t>Slc16a1</t> deletion in skeletal muscle (mKO). ( G ) Slc16a1 mRNA levels in different tissues of the mice. n = 5 for each group. ( H ) Body weight curves of the mice fed with normal chow diet. n = 10 to 11 for each group. ( I ) Quantification of body lean mass and fat mass by magnetic resonance imaging. n = 12 to 13 for each group. ( J ) Weight of different skeletal muscles. n = 4 for each group. ( K ) Results of metabolic cages to quantitate O 2 consumption, CO 2 production, respiratory exchange ratio (RER), and resting energy expenditure (REE) of the mice in light period (7:00 a.m. to 19:00 p.m.) and dark period (19:00 p.m. to 7:00 a.m.). n = 4 for each group. ( L ) Glucose tolerance test (GTT) of the mice with corresponding area under curve (AUC). n = 6 to 8 for each group. All data are shown as mean ± SEM. * P < 0.05, ** P < 0.01, and ns for nonsignificant. Glc, glucose; Pyr, pyruvate; Lac, lactate; Citr, citrate; Suc, succinate; Mal, malate.
Slc16a1 Flox/Flox Mice, supplied by Shanghai Model Organisms Center, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/background+c57bl+6/gat+1flox+flox+mice++c57bl6+j+background/pmc11204292-208-0-6
Average 90 stars, based on 1 article reviews
slc16a1 flox/flox mice - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Novartis ch25h-deficient mice (ch25h −/−) c57bl/6 background
Increased body weight and liver inflammation in mice fed an HFD for 20 weeks. A: Weight development in male HFD and STD <t>C57BL/6</t> mice. B: Epididymal fat weight as a percentage of total body weight after 20-week HFD feeding in C57BL/6 mice. C: Macroscopic aspect of livers from STD and HFD C57BL/6 mice. D: Representative H/E (left), Sirius Red (middle), and Oil Red O staining (right) of STD (upper panel) and HFD (bottom panel) wild-type mice, illustrating steatosis (white arrow), necroinflammation (inserts with magnification), cellular hypertrophy (black arrow), fat accumulation (middle panel), and collagen deposition (right panel). Scale bar: 100 µm. E: Serum liver function tests (AST and ALT) in HFD and STD mice. F: Liver tissue was analyzed for mRNA expression of Tnf, normalized to Hprt . Statistical analysis: Mann-Whitney U test, n ≥ 9. *** P < 0.001, ** P < 0.01, and * P < 0.05.
Ch25h Deficient Mice (Ch25h −/−) C57bl/6 Background, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/background+c57bl+6/ch25h+deficient+mice++ch25h++++++c57bl+6+background/pmc06602130-61-8-24
Average 90 stars, based on 1 article reviews
ch25h-deficient mice (ch25h −/−) c57bl/6 background - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Johns Hopkins HealthCare mct1 het mice
Increased body weight and liver inflammation in mice fed an HFD for 20 weeks. A: Weight development in male HFD and STD <t>C57BL/6</t> mice. B: Epididymal fat weight as a percentage of total body weight after 20-week HFD feeding in C57BL/6 mice. C: Macroscopic aspect of livers from STD and HFD C57BL/6 mice. D: Representative H/E (left), Sirius Red (middle), and Oil Red O staining (right) of STD (upper panel) and HFD (bottom panel) wild-type mice, illustrating steatosis (white arrow), necroinflammation (inserts with magnification), cellular hypertrophy (black arrow), fat accumulation (middle panel), and collagen deposition (right panel). Scale bar: 100 µm. E: Serum liver function tests (AST and ALT) in HFD and STD mice. F: Liver tissue was analyzed for mRNA expression of Tnf, normalized to Hprt . Statistical analysis: Mann-Whitney U test, n ≥ 9. *** P < 0.001, ** P < 0.01, and * P < 0.05.
Mct1 Het Mice, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/background+c57bl+6/heterozygous+mct1+null+mice+on+a+c57bl6+background/pmc04292924-49-3-32
Average 90 stars, based on 1 article reviews
mct1 het mice - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Lawrence Livermore National Security LLC sostdc1 -/- mice
Increased body weight and liver inflammation in mice fed an HFD for 20 weeks. A: Weight development in male HFD and STD <t>C57BL/6</t> mice. B: Epididymal fat weight as a percentage of total body weight after 20-week HFD feeding in C57BL/6 mice. C: Macroscopic aspect of livers from STD and HFD C57BL/6 mice. D: Representative H/E (left), Sirius Red (middle), and Oil Red O staining (right) of STD (upper panel) and HFD (bottom panel) wild-type mice, illustrating steatosis (white arrow), necroinflammation (inserts with magnification), cellular hypertrophy (black arrow), fat accumulation (middle panel), and collagen deposition (right panel). Scale bar: 100 µm. E: Serum liver function tests (AST and ALT) in HFD and STD mice. F: Liver tissue was analyzed for mRNA expression of Tnf, normalized to Hprt . Statistical analysis: Mann-Whitney U test, n ≥ 9. *** P < 0.001, ** P < 0.01, and * P < 0.05.
Sostdc1 / Mice, supplied by Lawrence Livermore National Security LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/background+c57bl+6/mouse++sostdc1+lacz+++mixed+c57bl+6+++fvb+n+++sjl+strain+background/bio_rxiv__387225-122-2-14
Average 90 stars, based on 1 article reviews
sostdc1 -/- mice - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Dr Raymond Laboratories Inc cd244 -/- mice on the c57bl/6 background
Increased body weight and liver inflammation in mice fed an HFD for 20 weeks. A: Weight development in male HFD and STD <t>C57BL/6</t> mice. B: Epididymal fat weight as a percentage of total body weight after 20-week HFD feeding in C57BL/6 mice. C: Macroscopic aspect of livers from STD and HFD C57BL/6 mice. D: Representative H/E (left), Sirius Red (middle), and Oil Red O staining (right) of STD (upper panel) and HFD (bottom panel) wild-type mice, illustrating steatosis (white arrow), necroinflammation (inserts with magnification), cellular hypertrophy (black arrow), fat accumulation (middle panel), and collagen deposition (right panel). Scale bar: 100 µm. E: Serum liver function tests (AST and ALT) in HFD and STD mice. F: Liver tissue was analyzed for mRNA expression of Tnf, normalized to Hprt . Statistical analysis: Mann-Whitney U test, n ≥ 9. *** P < 0.001, ** P < 0.01, and * P < 0.05.
Cd244 / Mice On The C57bl/6 Background, supplied by Dr Raymond Laboratories Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/background+c57bl+6/cd244+++++mice+on+the+c57bl+6+background/pmc04554987-32-5-13
Average 90 stars, based on 1 article reviews
cd244 -/- mice on the c57bl/6 background - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Merck KGaA bruce 4 c57bl/6 mescs
Increased body weight and liver inflammation in mice fed an HFD for 20 weeks. A: Weight development in male HFD and STD <t>C57BL/6</t> mice. B: Epididymal fat weight as a percentage of total body weight after 20-week HFD feeding in C57BL/6 mice. C: Macroscopic aspect of livers from STD and HFD C57BL/6 mice. D: Representative H/E (left), Sirius Red (middle), and Oil Red O staining (right) of STD (upper panel) and HFD (bottom panel) wild-type mice, illustrating steatosis (white arrow), necroinflammation (inserts with magnification), cellular hypertrophy (black arrow), fat accumulation (middle panel), and collagen deposition (right panel). Scale bar: 100 µm. E: Serum liver function tests (AST and ALT) in HFD and STD mice. F: Liver tissue was analyzed for mRNA expression of Tnf, normalized to Hprt . Statistical analysis: Mann-Whitney U test, n ≥ 9. *** P < 0.001, ** P < 0.01, and * P < 0.05.
Bruce 4 C57bl/6 Mescs, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/background+c57bl+6/mpges+1+++mice+on+a+c57bl+6+background/pmc04238020-135-10-4
Average 90 stars, based on 1 article reviews
bruce 4 c57bl/6 mescs - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Pasteur Institute hla-a*02:01/hla-drb1*01:01 transgenic h-2 class i-/class ii-knockout mice on a c57bl/6 background
Increased body weight and liver inflammation in mice fed an HFD for 20 weeks. A: Weight development in male HFD and STD <t>C57BL/6</t> mice. B: Epididymal fat weight as a percentage of total body weight after 20-week HFD feeding in C57BL/6 mice. C: Macroscopic aspect of livers from STD and HFD C57BL/6 mice. D: Representative H/E (left), Sirius Red (middle), and Oil Red O staining (right) of STD (upper panel) and HFD (bottom panel) wild-type mice, illustrating steatosis (white arrow), necroinflammation (inserts with magnification), cellular hypertrophy (black arrow), fat accumulation (middle panel), and collagen deposition (right panel). Scale bar: 100 µm. E: Serum liver function tests (AST and ALT) in HFD and STD mice. F: Liver tissue was analyzed for mRNA expression of Tnf, normalized to Hprt . Statistical analysis: Mann-Whitney U test, n ≥ 9. *** P < 0.001, ** P < 0.01, and * P < 0.05.
Hla A*02:01/Hla Drb1*01:01 Transgenic H 2 Class I /Class Ii Knockout Mice On A C57bl/6 Background, supplied by Pasteur Institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/background+c57bl+6/hla+a+02+01+hla+drb1+01+01+transgenic+h+2+class+i++class+ii+knockout+mice+on+a+c57bl+6+background/pmc04701504-55-9-15
Average 90 stars, based on 1 article reviews
hla-a*02:01/hla-drb1*01:01 transgenic h-2 class i-/class ii-knockout mice on a c57bl/6 background - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Ozgene Inc mice bearing loxp-flanked ( fl/fl ) alleles of ikzk2 (helios) on a c57bl/6 background
Increased body weight and liver inflammation in mice fed an HFD for 20 weeks. A: Weight development in male HFD and STD <t>C57BL/6</t> mice. B: Epididymal fat weight as a percentage of total body weight after 20-week HFD feeding in C57BL/6 mice. C: Macroscopic aspect of livers from STD and HFD C57BL/6 mice. D: Representative H/E (left), Sirius Red (middle), and Oil Red O staining (right) of STD (upper panel) and HFD (bottom panel) wild-type mice, illustrating steatosis (white arrow), necroinflammation (inserts with magnification), cellular hypertrophy (black arrow), fat accumulation (middle panel), and collagen deposition (right panel). Scale bar: 100 µm. E: Serum liver function tests (AST and ALT) in HFD and STD mice. F: Liver tissue was analyzed for mRNA expression of Tnf, normalized to Hprt . Statistical analysis: Mann-Whitney U test, n ≥ 9. *** P < 0.001, ** P < 0.01, and * P < 0.05.
Mice Bearing Loxp Flanked ( Fl/Fl ) Alleles Of Ikzk2 (Helios) On A C57bl/6 Background, supplied by Ozgene Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/background+c57bl+6/ly49e+ko+mice+c57bl+6+background/pmc04685018-42-13-18
Average 90 stars, based on 1 article reviews
mice bearing loxp-flanked ( fl/fl ) alleles of ikzk2 (helios) on a c57bl/6 background - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Crown Bioscience pd-1 hugemm mice (background: c57bl/6)
Enhancement of tumor clearance by the combination of blocking and nonblocking anti–PD-1 Abs in the PD-1 <t>HuGEMM</t> in vivo MC38 tumor model. (A) Experimental scheme. (B–E) Mice successfully engrafted with the MC38 tumor cell line were treated twice weekly with PBS control (B), NB01b (C), pembrolizumab or nivolumab (D), or a combination of NB01b with either pembrolizumab or nivolumab (E), with tumor volumes measured in parallel. A collective analysis of three separate studies with n = 9–10 mice per arm per study is presented in A–D. P values determined by pairwise comparison using a mixed-effect linear model showed that all Ab arms of the study had reduced tumor growth compared with the vehicle control arm. (F) Suppression of tumor volume in mice engrafted with PDL-1–high MC38 cell line with either single or the combination of blocking and nonblocking anti–PD-1 Abs. Blocking (pembrolizumab or nivolumab) and nonblocking (NB01b) anti–PD-1 Ab monotherapies exerted equivalent suppression of tumor growth and mean percent tumor inhibition. Modeling of the cubic root transformed tumor volume in three separate studies as a function of time demonstrated a statistically significant reduction in tumor volume over time for the anti–PD-1 combination therapy relative to anti–PD-1 monotherapies. (G) Combination anti–PD-1 Ab therapy significantly enhanced the proportion of mice that controlled tumor growth (9 out of 19 mice) relative to Ab monotherapies (13 out of 59 mice). Survival analysis for a study performed using NB01b and nivolumab, with statistical differences determined using the log-rank test. Graphs show the mean ± SEM, unless otherwise indicated. *, P = 0.0223; **, P < 0.008; ***, P = 0.0005; ****, P < 0.0001.
Pd 1 Hugemm Mice (Background: C57bl/6), supplied by Crown Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/background+c57bl+6/pd+1+hugemm+mice++background++c57bl+6+/pmc06605749-292-7-15
Average 90 stars, based on 1 article reviews
pd-1 hugemm mice (background: c57bl/6) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
JCRB Cell Bank hepa1-6, a murine hepatoma cell line derived from a c57bl/6 mouse
Efficacy of G47Δ in combination with CTLA-4 or PD-1 inhibition in a murine subcutaneous AKR tumor model (A−D) Effects of G47Δ or CTLA-4 inhibition, either alone or in combination, on tumor growth in the murine subcutaneous AKR tumor model. (A) Experimental design. <t>C57BL/6</t> mice harboring unilateral subcutaneous AKR tumors were given intratumoral injections with G47Δ (5 × 10 6 PFUs on days 0 and 3) or mock in combination with intraperitoneal injections with the anti-CTLA-4 antibody (25 μg on days 0, 3, and 6) as indicated. (B) Delayed tumor growth was observed with either G47Δ (p < 0.05) or CTLA-4 inhibition (p < 0.01) alone, but the combination treatment was associated with a significant decrease in tumor growth compared with each monotherapy (versus G47Δ, p < 0.001; versus αCTLA-4, p < 0.01). The results are presented as the mean ± SEM (n = 8 per group). (C) Individual tumor growth curves of AKR tumors. The combination therapy achieved a cure in 5/8 animals. (D) Kaplan-Meier survival curves. The combination therapy resulted in significantly prolonged survival (p < 0.001 versus control; G47Δ, p < 0.01 versus αCTLA-4). (E−H) Efficacies of G47Δ and PD-1 inhibition, either alone or in combination, in the murine subcutaneous AKR tumor model. (E) Experimental design. C57BL/6 mice harboring subcutaneous AKR tumors were treated with G47Δ (5 × 10 6 PFUs) or mock together with intraperitoneal injections with the anti-PD-1 antibody (100 μg) as indicated. (F) Tumor growth was significantly inhibited by the anti-PD-1 antibody alone (versus control, p < 0.001). The efficacy of G47Δ combined with systemic PD-1 inhibition was equivalent to that of PD-1 inhibition alone. The results are presented as the mean ± SEM (n = 7 per group). (G) Individual tumor growth curves. The combination therapy did not yield a cure. (H) Kaplan-Meier survival curves. One-way ANOVA followed by Dunnett’s test was used for the comparisons of tumor growth. For survival analysis, the log-rank test followed by Holm’s sequential Bonferroni corrections was used to determine statistical significance (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ns, not significant).
Hepa1 6, A Murine Hepatoma Cell Line Derived From A C57bl/6 Mouse, supplied by JCRB Cell Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/background+c57bl+6/c57bl+6+background+++mus+musculus++/pmc08413837-158-9-14
Average 90 stars, based on 1 article reviews
hepa1-6, a murine hepatoma cell line derived from a c57bl/6 mouse - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


FGF21 deletion accelerated and aggravated diabetes-induced aortic thickening. At indicated time points after diabetes onset, histological change of aorta was evaluated by H&E staining ( a ) and aorta thickness was measured using Image Pro Plus 6.0 software ( b ). Data are presented as means ± SD, n ≥ 5 for each group. * p < 0.05 vs WT Ctrl group; # p < 0.05 vs FGF21KO Ctrl group; & p < 0.05 vs WT DM group. Bar = 50 μm. Ctrl: control; DM: diabetes mellitus; WT: wild type; FGF21KO: FGF21 knockout; m: month(s)

Journal: Cardiovascular Diabetology

Article Title: Fibroblast growth factor 21 deletion aggravates diabetes-induced pathogenic changes in the aorta in type 1 diabetic mice

doi: 10.1186/s12933-015-0241-0

Figure Lengend Snippet: FGF21 deletion accelerated and aggravated diabetes-induced aortic thickening. At indicated time points after diabetes onset, histological change of aorta was evaluated by H&E staining ( a ) and aorta thickness was measured using Image Pro Plus 6.0 software ( b ). Data are presented as means ± SD, n ≥ 5 for each group. * p < 0.05 vs WT Ctrl group; # p < 0.05 vs FGF21KO Ctrl group; & p < 0.05 vs WT DM group. Bar = 50 μm. Ctrl: control; DM: diabetes mellitus; WT: wild type; FGF21KO: FGF21 knockout; m: month(s)

Article Snippet: The present study used male FGF21KO mice with C57 BL/6 J background (gifted by Dr. Steve Kliewer, University of Texas Southwestern Medical Center) [ ] and wild type (WT) C57 BL/6 J mice purchased from Jackson Laboratory (Bar Harbor, Maine).

Techniques: Staining, Software, Control, Knock-Out

FGF21 deletion accelerated and aggravated diabetes-induced aortic fibrosis. At indicated time points after diabetes onset, aortic fibrosis was evaluated by Sirius Red staining of collagen accumulation ( a, b ) and immunohistochemical staining of CTGF expression ( c, d ). Data are presented as means ± SD, n ≥ 5 for each group. * p < 0.05 vs WT Ctrl group; # p < 0.05 vs FGF21KO Ctrl group; & p < 0.05 vs WT DM group. Bar = 50 μm. Abbreviations are the same as the Fig.

Journal: Cardiovascular Diabetology

Article Title: Fibroblast growth factor 21 deletion aggravates diabetes-induced pathogenic changes in the aorta in type 1 diabetic mice

doi: 10.1186/s12933-015-0241-0

Figure Lengend Snippet: FGF21 deletion accelerated and aggravated diabetes-induced aortic fibrosis. At indicated time points after diabetes onset, aortic fibrosis was evaluated by Sirius Red staining of collagen accumulation ( a, b ) and immunohistochemical staining of CTGF expression ( c, d ). Data are presented as means ± SD, n ≥ 5 for each group. * p < 0.05 vs WT Ctrl group; # p < 0.05 vs FGF21KO Ctrl group; & p < 0.05 vs WT DM group. Bar = 50 μm. Abbreviations are the same as the Fig.

Article Snippet: The present study used male FGF21KO mice with C57 BL/6 J background (gifted by Dr. Steve Kliewer, University of Texas Southwestern Medical Center) [ ] and wild type (WT) C57 BL/6 J mice purchased from Jackson Laboratory (Bar Harbor, Maine).

Techniques: Staining, Immunohistochemical staining, Expressing

FGF21 deficiency aggravated diabetes-induced inflammation. At indicated time points after diabetes onset, aortic inflammation was evaluated by immunohistochemical staining of TGF-β expression ( a, b ) and TNF-α ( c, d ). Plasma IL-6 was detected by ELISA ( e ). Data are presented as means ± SD, n ≥ 5 for each group. * p < 0.05 vs WT Ctrl group; # p < 0.05 vs FGF21KO Ctrl group; & p < 0.05 vs WT DM group. Bar = 50 μm. Abbreviations are the same as the Fig.

Journal: Cardiovascular Diabetology

Article Title: Fibroblast growth factor 21 deletion aggravates diabetes-induced pathogenic changes in the aorta in type 1 diabetic mice

doi: 10.1186/s12933-015-0241-0

Figure Lengend Snippet: FGF21 deficiency aggravated diabetes-induced inflammation. At indicated time points after diabetes onset, aortic inflammation was evaluated by immunohistochemical staining of TGF-β expression ( a, b ) and TNF-α ( c, d ). Plasma IL-6 was detected by ELISA ( e ). Data are presented as means ± SD, n ≥ 5 for each group. * p < 0.05 vs WT Ctrl group; # p < 0.05 vs FGF21KO Ctrl group; & p < 0.05 vs WT DM group. Bar = 50 μm. Abbreviations are the same as the Fig.

Article Snippet: The present study used male FGF21KO mice with C57 BL/6 J background (gifted by Dr. Steve Kliewer, University of Texas Southwestern Medical Center) [ ] and wild type (WT) C57 BL/6 J mice purchased from Jackson Laboratory (Bar Harbor, Maine).

Techniques: Immunohistochemical staining, Staining, Expressing, Clinical Proteomics, Enzyme-linked Immunosorbent Assay

FGF21 deficiency accelerated diabetes-induced cell apoptosis. At indicated time points after diabetes onset, cell apoptosis was evaluated by TUNEL staining ( a, b ). Data are presented as means ± SD, n ≥ 5 for each group. * p < 0.05 vs WT Ctrl group; # p < 0.05 vs FGF21KO Ctrl group. Bar = 50 μm. Abbreviations are the same as the Fig.

Journal: Cardiovascular Diabetology

Article Title: Fibroblast growth factor 21 deletion aggravates diabetes-induced pathogenic changes in the aorta in type 1 diabetic mice

doi: 10.1186/s12933-015-0241-0

Figure Lengend Snippet: FGF21 deficiency accelerated diabetes-induced cell apoptosis. At indicated time points after diabetes onset, cell apoptosis was evaluated by TUNEL staining ( a, b ). Data are presented as means ± SD, n ≥ 5 for each group. * p < 0.05 vs WT Ctrl group; # p < 0.05 vs FGF21KO Ctrl group. Bar = 50 μm. Abbreviations are the same as the Fig.

Article Snippet: The present study used male FGF21KO mice with C57 BL/6 J background (gifted by Dr. Steve Kliewer, University of Texas Southwestern Medical Center) [ ] and wild type (WT) C57 BL/6 J mice purchased from Jackson Laboratory (Bar Harbor, Maine).

Techniques: TUNEL Assay, Staining

FGF21 deficiency accelerated and aggravated diabetes-induced oxidative stress. At indicated time points after diabetes onset, oxidative stress was evaluated by immunohistochemical staining of 3-NT ( a, b ) and 4-HNE ( c, d ). Antioxidative response was also evaluated by immunohistochemical staining of transcription factor Nrf2 ( e,f ). Data are presented as means ± SD, n ≥ 5 for each group. * p < 0.05 vs WT Ctrl group; # p < 0.05 vs FGF21KO Ctrl group; & p < 0.05 vs WT DM group. Bar = 50 μm. Abbreviations are the same as the Fig.

Journal: Cardiovascular Diabetology

Article Title: Fibroblast growth factor 21 deletion aggravates diabetes-induced pathogenic changes in the aorta in type 1 diabetic mice

doi: 10.1186/s12933-015-0241-0

Figure Lengend Snippet: FGF21 deficiency accelerated and aggravated diabetes-induced oxidative stress. At indicated time points after diabetes onset, oxidative stress was evaluated by immunohistochemical staining of 3-NT ( a, b ) and 4-HNE ( c, d ). Antioxidative response was also evaluated by immunohistochemical staining of transcription factor Nrf2 ( e,f ). Data are presented as means ± SD, n ≥ 5 for each group. * p < 0.05 vs WT Ctrl group; # p < 0.05 vs FGF21KO Ctrl group; & p < 0.05 vs WT DM group. Bar = 50 μm. Abbreviations are the same as the Fig.

Article Snippet: The present study used male FGF21KO mice with C57 BL/6 J background (gifted by Dr. Steve Kliewer, University of Texas Southwestern Medical Center) [ ] and wild type (WT) C57 BL/6 J mice purchased from Jackson Laboratory (Bar Harbor, Maine).

Techniques: Immunohistochemical staining, Staining

FGF21 deficiency accelerated and aggravated the impairment of eNOS activation in diabetes. At indicated time points after diabetes onset, eNOS activation was evaluated by immunohistochemical staining of p-eNOS (Ser-1177) ( a, b ). Data are presented as means ± SD, n ≥ 5 for each group. * p < 0.05 vs WT Ctrl group; # p < 0.05 vs FGF21KO Ctrl group; & p < 0.05 vs WT DM group. Bar = 50 μm. Abbreviations are the same as the Fig.

Journal: Cardiovascular Diabetology

Article Title: Fibroblast growth factor 21 deletion aggravates diabetes-induced pathogenic changes in the aorta in type 1 diabetic mice

doi: 10.1186/s12933-015-0241-0

Figure Lengend Snippet: FGF21 deficiency accelerated and aggravated the impairment of eNOS activation in diabetes. At indicated time points after diabetes onset, eNOS activation was evaluated by immunohistochemical staining of p-eNOS (Ser-1177) ( a, b ). Data are presented as means ± SD, n ≥ 5 for each group. * p < 0.05 vs WT Ctrl group; # p < 0.05 vs FGF21KO Ctrl group; & p < 0.05 vs WT DM group. Bar = 50 μm. Abbreviations are the same as the Fig.

Article Snippet: The present study used male FGF21KO mice with C57 BL/6 J background (gifted by Dr. Steve Kliewer, University of Texas Southwestern Medical Center) [ ] and wild type (WT) C57 BL/6 J mice purchased from Jackson Laboratory (Bar Harbor, Maine).

Techniques: Activation Assay, Immunohistochemical staining, Staining

FGF21 administration reversed pathologic changes in the aorta of FGF21KO DM mice. In a type 1 diabetes model, FGF21 administration reversed aortic thickening ( a ), fibrosis ( b ) and cell apoptosis ( c ) in the aorta of FGF21KO DM mice. Data are presented as means ± SD, n ≥ 5 for each group. * p < 0.05 vs WT Ctrl group; #: P < 0.05 vs. FGF21KO Ctrl; @: P < 0.05 vs. FGF21KO DM; $: P < 0.05 vs. WT DM. Bar = 50 μm. Abbreviations are the same as the Fig. . FGF21KO DM + FGF21: FGF21KO DM mice received FGF21 administration

Journal: Cardiovascular Diabetology

Article Title: Fibroblast growth factor 21 deletion aggravates diabetes-induced pathogenic changes in the aorta in type 1 diabetic mice

doi: 10.1186/s12933-015-0241-0

Figure Lengend Snippet: FGF21 administration reversed pathologic changes in the aorta of FGF21KO DM mice. In a type 1 diabetes model, FGF21 administration reversed aortic thickening ( a ), fibrosis ( b ) and cell apoptosis ( c ) in the aorta of FGF21KO DM mice. Data are presented as means ± SD, n ≥ 5 for each group. * p < 0.05 vs WT Ctrl group; #: P < 0.05 vs. FGF21KO Ctrl; @: P < 0.05 vs. FGF21KO DM; $: P < 0.05 vs. WT DM. Bar = 50 μm. Abbreviations are the same as the Fig. . FGF21KO DM + FGF21: FGF21KO DM mice received FGF21 administration

Article Snippet: The present study used male FGF21KO mice with C57 BL/6 J background (gifted by Dr. Steve Kliewer, University of Texas Southwestern Medical Center) [ ] and wild type (WT) C57 BL/6 J mice purchased from Jackson Laboratory (Bar Harbor, Maine).

Techniques:

( A ) Schematic showing metabolic pathways of glucose and lactate between blood and skeletal muscle in mice after infusion of [U- 13 C] glucose or [U- 13 C] lactate. ( B ) Normalized labeling from 2.5-hour [U- 13 C] glucose or [U- 13 C] lactate infusion of glycolytic products in QUA, TA, GAS, and SOL. n = 2 to 3. ( C ) Schematic of TCA intermediates, for example, malate, produced from [U- 13 C] glucose or [U- 13 C] lactate by jugular vein catheterizing in tissues. ( D ) Direct sources of muscle lactate and malate from circulatory labeled glucose and lactate. n = 2 to 3. ( E ) Immunofluorescence staining of MCT1 (blue) with muscle fiber markers for type IIA (green, recognized by anti-MyHC IIA), type IIB (purple, recognized by anti-MyHC IIB), and type IIX (unstained). Scale bars, 100 μm. ( F ) Scheme showing the strategy of generating mouse with Slc16a1 deletion in skeletal muscle (mKO). ( G ) Slc16a1 mRNA levels in different tissues of the mice. n = 5 for each group. ( H ) Body weight curves of the mice fed with normal chow diet. n = 10 to 11 for each group. ( I ) Quantification of body lean mass and fat mass by magnetic resonance imaging. n = 12 to 13 for each group. ( J ) Weight of different skeletal muscles. n = 4 for each group. ( K ) Results of metabolic cages to quantitate O 2 consumption, CO 2 production, respiratory exchange ratio (RER), and resting energy expenditure (REE) of the mice in light period (7:00 a.m. to 19:00 p.m.) and dark period (19:00 p.m. to 7:00 a.m.). n = 4 for each group. ( L ) Glucose tolerance test (GTT) of the mice with corresponding area under curve (AUC). n = 6 to 8 for each group. All data are shown as mean ± SEM. * P < 0.05, ** P < 0.01, and ns for nonsignificant. Glc, glucose; Pyr, pyruvate; Lac, lactate; Citr, citrate; Suc, succinate; Mal, malate.

Journal: Science Advances

Article Title: Lactate transported by MCT1 plays an active role in promoting mitochondrial biogenesis and enhancing TCA flux in skeletal muscle

doi: 10.1126/sciadv.adn4508

Figure Lengend Snippet: ( A ) Schematic showing metabolic pathways of glucose and lactate between blood and skeletal muscle in mice after infusion of [U- 13 C] glucose or [U- 13 C] lactate. ( B ) Normalized labeling from 2.5-hour [U- 13 C] glucose or [U- 13 C] lactate infusion of glycolytic products in QUA, TA, GAS, and SOL. n = 2 to 3. ( C ) Schematic of TCA intermediates, for example, malate, produced from [U- 13 C] glucose or [U- 13 C] lactate by jugular vein catheterizing in tissues. ( D ) Direct sources of muscle lactate and malate from circulatory labeled glucose and lactate. n = 2 to 3. ( E ) Immunofluorescence staining of MCT1 (blue) with muscle fiber markers for type IIA (green, recognized by anti-MyHC IIA), type IIB (purple, recognized by anti-MyHC IIB), and type IIX (unstained). Scale bars, 100 μm. ( F ) Scheme showing the strategy of generating mouse with Slc16a1 deletion in skeletal muscle (mKO). ( G ) Slc16a1 mRNA levels in different tissues of the mice. n = 5 for each group. ( H ) Body weight curves of the mice fed with normal chow diet. n = 10 to 11 for each group. ( I ) Quantification of body lean mass and fat mass by magnetic resonance imaging. n = 12 to 13 for each group. ( J ) Weight of different skeletal muscles. n = 4 for each group. ( K ) Results of metabolic cages to quantitate O 2 consumption, CO 2 production, respiratory exchange ratio (RER), and resting energy expenditure (REE) of the mice in light period (7:00 a.m. to 19:00 p.m.) and dark period (19:00 p.m. to 7:00 a.m.). n = 4 for each group. ( L ) Glucose tolerance test (GTT) of the mice with corresponding area under curve (AUC). n = 6 to 8 for each group. All data are shown as mean ± SEM. * P < 0.05, ** P < 0.01, and ns for nonsignificant. Glc, glucose; Pyr, pyruvate; Lac, lactate; Citr, citrate; Suc, succinate; Mal, malate.

Article Snippet: Slc16a1 Flox/Flox mice were obtained from Shanghai Model Organisms Center (Shanghai, China) as previously described ( ).

Techniques: Labeling, Produced, Immunofluorescence, Staining, Magnetic Resonance Imaging, Muscles

Increased body weight and liver inflammation in mice fed an HFD for 20 weeks. A: Weight development in male HFD and STD C57BL/6 mice. B: Epididymal fat weight as a percentage of total body weight after 20-week HFD feeding in C57BL/6 mice. C: Macroscopic aspect of livers from STD and HFD C57BL/6 mice. D: Representative H/E (left), Sirius Red (middle), and Oil Red O staining (right) of STD (upper panel) and HFD (bottom panel) wild-type mice, illustrating steatosis (white arrow), necroinflammation (inserts with magnification), cellular hypertrophy (black arrow), fat accumulation (middle panel), and collagen deposition (right panel). Scale bar: 100 µm. E: Serum liver function tests (AST and ALT) in HFD and STD mice. F: Liver tissue was analyzed for mRNA expression of Tnf, normalized to Hprt . Statistical analysis: Mann-Whitney U test, n ≥ 9. *** P < 0.001, ** P < 0.01, and * P < 0.05.

Journal: Journal of Lipid Research

Article Title: Elevated oxysterol levels in human and mouse livers reflect nonalcoholic steatohepatitis [S]

doi: 10.1194/jlr.M093229

Figure Lengend Snippet: Increased body weight and liver inflammation in mice fed an HFD for 20 weeks. A: Weight development in male HFD and STD C57BL/6 mice. B: Epididymal fat weight as a percentage of total body weight after 20-week HFD feeding in C57BL/6 mice. C: Macroscopic aspect of livers from STD and HFD C57BL/6 mice. D: Representative H/E (left), Sirius Red (middle), and Oil Red O staining (right) of STD (upper panel) and HFD (bottom panel) wild-type mice, illustrating steatosis (white arrow), necroinflammation (inserts with magnification), cellular hypertrophy (black arrow), fat accumulation (middle panel), and collagen deposition (right panel). Scale bar: 100 µm. E: Serum liver function tests (AST and ALT) in HFD and STD mice. F: Liver tissue was analyzed for mRNA expression of Tnf, normalized to Hprt . Statistical analysis: Mann-Whitney U test, n ≥ 9. *** P < 0.001, ** P < 0.01, and * P < 0.05.

Article Snippet: CH25H-deficient mice ( Ch25h −/− ) in a C57BL/6 background and EBI2-deficient mice ( Ebi2 −/− ) in a C57BL/6 background were provided by Novartis Institutes for BioMedical Research ( , ).

Techniques: Staining, Expressing, MANN-WHITNEY

Liver oxysterol levels in a murine model of NAFLD/NASH. Eight-week-old male C57BL/6 mice were fed an HFD or STD for 20 weeks. Levels of the indicated oxysterol in the liver tissue of HFD (black squares: NASH; white squares: NAFLD) and STD controls were measured by LC-MS. Statistical analysis: Mann-Whitney U test ( n STD = 8, ≥3 valid data points; n HFD = 10, ≥5 valid data points). *** P < 0.001, ** P < 0.01, and * P < 0.05.

Journal: Journal of Lipid Research

Article Title: Elevated oxysterol levels in human and mouse livers reflect nonalcoholic steatohepatitis [S]

doi: 10.1194/jlr.M093229

Figure Lengend Snippet: Liver oxysterol levels in a murine model of NAFLD/NASH. Eight-week-old male C57BL/6 mice were fed an HFD or STD for 20 weeks. Levels of the indicated oxysterol in the liver tissue of HFD (black squares: NASH; white squares: NAFLD) and STD controls were measured by LC-MS. Statistical analysis: Mann-Whitney U test ( n STD = 8, ≥3 valid data points; n HFD = 10, ≥5 valid data points). *** P < 0.001, ** P < 0.01, and * P < 0.05.

Article Snippet: CH25H-deficient mice ( Ch25h −/− ) in a C57BL/6 background and EBI2-deficient mice ( Ebi2 −/− ) in a C57BL/6 background were provided by Novartis Institutes for BioMedical Research ( , ).

Techniques: Liquid Chromatography with Mass Spectroscopy, MANN-WHITNEY

Enhancement of tumor clearance by the combination of blocking and nonblocking anti–PD-1 Abs in the PD-1 HuGEMM in vivo MC38 tumor model. (A) Experimental scheme. (B–E) Mice successfully engrafted with the MC38 tumor cell line were treated twice weekly with PBS control (B), NB01b (C), pembrolizumab or nivolumab (D), or a combination of NB01b with either pembrolizumab or nivolumab (E), with tumor volumes measured in parallel. A collective analysis of three separate studies with n = 9–10 mice per arm per study is presented in A–D. P values determined by pairwise comparison using a mixed-effect linear model showed that all Ab arms of the study had reduced tumor growth compared with the vehicle control arm. (F) Suppression of tumor volume in mice engrafted with PDL-1–high MC38 cell line with either single or the combination of blocking and nonblocking anti–PD-1 Abs. Blocking (pembrolizumab or nivolumab) and nonblocking (NB01b) anti–PD-1 Ab monotherapies exerted equivalent suppression of tumor growth and mean percent tumor inhibition. Modeling of the cubic root transformed tumor volume in three separate studies as a function of time demonstrated a statistically significant reduction in tumor volume over time for the anti–PD-1 combination therapy relative to anti–PD-1 monotherapies. (G) Combination anti–PD-1 Ab therapy significantly enhanced the proportion of mice that controlled tumor growth (9 out of 19 mice) relative to Ab monotherapies (13 out of 59 mice). Survival analysis for a study performed using NB01b and nivolumab, with statistical differences determined using the log-rank test. Graphs show the mean ± SEM, unless otherwise indicated. *, P = 0.0223; **, P < 0.008; ***, P = 0.0005; ****, P < 0.0001.

Journal: The Journal of Experimental Medicine

Article Title: Tumor suppression of novel anti–PD-1 antibodies mediated through CD28 costimulatory pathway

doi: 10.1084/jem.20182359

Figure Lengend Snippet: Enhancement of tumor clearance by the combination of blocking and nonblocking anti–PD-1 Abs in the PD-1 HuGEMM in vivo MC38 tumor model. (A) Experimental scheme. (B–E) Mice successfully engrafted with the MC38 tumor cell line were treated twice weekly with PBS control (B), NB01b (C), pembrolizumab or nivolumab (D), or a combination of NB01b with either pembrolizumab or nivolumab (E), with tumor volumes measured in parallel. A collective analysis of three separate studies with n = 9–10 mice per arm per study is presented in A–D. P values determined by pairwise comparison using a mixed-effect linear model showed that all Ab arms of the study had reduced tumor growth compared with the vehicle control arm. (F) Suppression of tumor volume in mice engrafted with PDL-1–high MC38 cell line with either single or the combination of blocking and nonblocking anti–PD-1 Abs. Blocking (pembrolizumab or nivolumab) and nonblocking (NB01b) anti–PD-1 Ab monotherapies exerted equivalent suppression of tumor growth and mean percent tumor inhibition. Modeling of the cubic root transformed tumor volume in three separate studies as a function of time demonstrated a statistically significant reduction in tumor volume over time for the anti–PD-1 combination therapy relative to anti–PD-1 monotherapies. (G) Combination anti–PD-1 Ab therapy significantly enhanced the proportion of mice that controlled tumor growth (9 out of 19 mice) relative to Ab monotherapies (13 out of 59 mice). Survival analysis for a study performed using NB01b and nivolumab, with statistical differences determined using the log-rank test. Graphs show the mean ± SEM, unless otherwise indicated. *, P = 0.0223; **, P < 0.008; ***, P = 0.0005; ****, P < 0.0001.

Article Snippet: The in vivo tumor model studies using PD-1 HuGEMM mice (background: C57BL/6) were performed at CrownBio (Taicang, China) in three separate MC38 studies and one B16F10 tumor study.

Techniques: Blocking Assay, In Vivo, Control, Comparison, Inhibition, Transformation Assay

Blocking and nonblocking anti–PD-1 Abs suppress tumor growth and prolong survival of mice implanted with B16F10 cells in the PD-1 HuGEMM in vivo tumor model. (A) Experimental scheme. (B–E) Mice successfully engrafted with the poorly immunogenic B16F10 tumor cell line were treated twice weekly with PBS control (B), NB01b (C), pembrolizumab (D), or a combination of NB01b and pembrolizumab (E), with tumor volumes measured in parallel in the treatment ( n = 10 mice) and control (vehicle; n = 10 mice) groups. P values determined by pairwise comparison using a mixed-effect linear model showed that blocking (pembrolizumab), nonblocking (NB01b), and combination anti–PD-1 Ab therapies had reduced tumor volume growth relative to the vehicle control. (F) Survival analysis with statistical difference determined using the log-rank test. Graphs show the mean ± SEM. **, P = 0.008; ****, P < 0.0001.

Journal: The Journal of Experimental Medicine

Article Title: Tumor suppression of novel anti–PD-1 antibodies mediated through CD28 costimulatory pathway

doi: 10.1084/jem.20182359

Figure Lengend Snippet: Blocking and nonblocking anti–PD-1 Abs suppress tumor growth and prolong survival of mice implanted with B16F10 cells in the PD-1 HuGEMM in vivo tumor model. (A) Experimental scheme. (B–E) Mice successfully engrafted with the poorly immunogenic B16F10 tumor cell line were treated twice weekly with PBS control (B), NB01b (C), pembrolizumab (D), or a combination of NB01b and pembrolizumab (E), with tumor volumes measured in parallel in the treatment ( n = 10 mice) and control (vehicle; n = 10 mice) groups. P values determined by pairwise comparison using a mixed-effect linear model showed that blocking (pembrolizumab), nonblocking (NB01b), and combination anti–PD-1 Ab therapies had reduced tumor volume growth relative to the vehicle control. (F) Survival analysis with statistical difference determined using the log-rank test. Graphs show the mean ± SEM. **, P = 0.008; ****, P < 0.0001.

Article Snippet: The in vivo tumor model studies using PD-1 HuGEMM mice (background: C57BL/6) were performed at CrownBio (Taicang, China) in three separate MC38 studies and one B16F10 tumor study.

Techniques: Blocking Assay, In Vivo, Control, Comparison

Efficacy of G47Δ in combination with CTLA-4 or PD-1 inhibition in a murine subcutaneous AKR tumor model (A−D) Effects of G47Δ or CTLA-4 inhibition, either alone or in combination, on tumor growth in the murine subcutaneous AKR tumor model. (A) Experimental design. C57BL/6 mice harboring unilateral subcutaneous AKR tumors were given intratumoral injections with G47Δ (5 × 10 6 PFUs on days 0 and 3) or mock in combination with intraperitoneal injections with the anti-CTLA-4 antibody (25 μg on days 0, 3, and 6) as indicated. (B) Delayed tumor growth was observed with either G47Δ (p < 0.05) or CTLA-4 inhibition (p < 0.01) alone, but the combination treatment was associated with a significant decrease in tumor growth compared with each monotherapy (versus G47Δ, p < 0.001; versus αCTLA-4, p < 0.01). The results are presented as the mean ± SEM (n = 8 per group). (C) Individual tumor growth curves of AKR tumors. The combination therapy achieved a cure in 5/8 animals. (D) Kaplan-Meier survival curves. The combination therapy resulted in significantly prolonged survival (p < 0.001 versus control; G47Δ, p < 0.01 versus αCTLA-4). (E−H) Efficacies of G47Δ and PD-1 inhibition, either alone or in combination, in the murine subcutaneous AKR tumor model. (E) Experimental design. C57BL/6 mice harboring subcutaneous AKR tumors were treated with G47Δ (5 × 10 6 PFUs) or mock together with intraperitoneal injections with the anti-PD-1 antibody (100 μg) as indicated. (F) Tumor growth was significantly inhibited by the anti-PD-1 antibody alone (versus control, p < 0.001). The efficacy of G47Δ combined with systemic PD-1 inhibition was equivalent to that of PD-1 inhibition alone. The results are presented as the mean ± SEM (n = 7 per group). (G) Individual tumor growth curves. The combination therapy did not yield a cure. (H) Kaplan-Meier survival curves. One-way ANOVA followed by Dunnett’s test was used for the comparisons of tumor growth. For survival analysis, the log-rank test followed by Holm’s sequential Bonferroni corrections was used to determine statistical significance (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ns, not significant).

Journal: Molecular Therapy Oncolytics

Article Title: Oncolytic herpes virus G47Δ works synergistically with CTLA-4 inhibition via dynamic intratumoral immune modulation

doi: 10.1016/j.omto.2021.05.004

Figure Lengend Snippet: Efficacy of G47Δ in combination with CTLA-4 or PD-1 inhibition in a murine subcutaneous AKR tumor model (A−D) Effects of G47Δ or CTLA-4 inhibition, either alone or in combination, on tumor growth in the murine subcutaneous AKR tumor model. (A) Experimental design. C57BL/6 mice harboring unilateral subcutaneous AKR tumors were given intratumoral injections with G47Δ (5 × 10 6 PFUs on days 0 and 3) or mock in combination with intraperitoneal injections with the anti-CTLA-4 antibody (25 μg on days 0, 3, and 6) as indicated. (B) Delayed tumor growth was observed with either G47Δ (p < 0.05) or CTLA-4 inhibition (p < 0.01) alone, but the combination treatment was associated with a significant decrease in tumor growth compared with each monotherapy (versus G47Δ, p < 0.001; versus αCTLA-4, p < 0.01). The results are presented as the mean ± SEM (n = 8 per group). (C) Individual tumor growth curves of AKR tumors. The combination therapy achieved a cure in 5/8 animals. (D) Kaplan-Meier survival curves. The combination therapy resulted in significantly prolonged survival (p < 0.001 versus control; G47Δ, p < 0.01 versus αCTLA-4). (E−H) Efficacies of G47Δ and PD-1 inhibition, either alone or in combination, in the murine subcutaneous AKR tumor model. (E) Experimental design. C57BL/6 mice harboring subcutaneous AKR tumors were treated with G47Δ (5 × 10 6 PFUs) or mock together with intraperitoneal injections with the anti-PD-1 antibody (100 μg) as indicated. (F) Tumor growth was significantly inhibited by the anti-PD-1 antibody alone (versus control, p < 0.001). The efficacy of G47Δ combined with systemic PD-1 inhibition was equivalent to that of PD-1 inhibition alone. The results are presented as the mean ± SEM (n = 7 per group). (G) Individual tumor growth curves. The combination therapy did not yield a cure. (H) Kaplan-Meier survival curves. One-way ANOVA followed by Dunnett’s test was used for the comparisons of tumor growth. For survival analysis, the log-rank test followed by Holm’s sequential Bonferroni corrections was used to determine statistical significance (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ns, not significant).

Article Snippet: Hepa1-6, a murine hepatoma cell line derived from a C57BL/6 mouse, was obtained from Japanese Collection of Research Bioresources (Osaka, Japan).

Techniques: Inhibition

Tumor-infiltrating lymphocytes in subcutaneous AKR tumors treated with the combination of G47Δ and CTLA-4 inhibition C57BL/6 mice harboring subcutaneous AKR tumors were treated according to the schedule shown in <xref ref-type=Figure 2 A. Tumor-infiltrating immune cells were analyzed by flow cytometry 7 days after the initial treatments. Comparisons of absolute numbers of (A) CD3 cells, (B) CD4 + T cells, (C) CD8 + T cells, and (D) Tregs (CD4 + Foxp3 + ) per gram of tumor tissue. (E) The percentage of Tregs, gated on CD4 + T cells. (F) The ratio of CD8 + T cells to Tregs. (G) The percentage of CD3, CD8 + , CD4 + , and Tregs gated on CD45 cells. Results are representative of two independent experiments with 7 animals per group, and bars represent the SEM. One-way ANOVA followed by Dunnett’s test was used to determine statistical significance (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ns, not significant). " width="100%" height="100%">

Journal: Molecular Therapy Oncolytics

Article Title: Oncolytic herpes virus G47Δ works synergistically with CTLA-4 inhibition via dynamic intratumoral immune modulation

doi: 10.1016/j.omto.2021.05.004

Figure Lengend Snippet: Tumor-infiltrating lymphocytes in subcutaneous AKR tumors treated with the combination of G47Δ and CTLA-4 inhibition C57BL/6 mice harboring subcutaneous AKR tumors were treated according to the schedule shown in Figure 2 A. Tumor-infiltrating immune cells were analyzed by flow cytometry 7 days after the initial treatments. Comparisons of absolute numbers of (A) CD3 cells, (B) CD4 + T cells, (C) CD8 + T cells, and (D) Tregs (CD4 + Foxp3 + ) per gram of tumor tissue. (E) The percentage of Tregs, gated on CD4 + T cells. (F) The ratio of CD8 + T cells to Tregs. (G) The percentage of CD3, CD8 + , CD4 + , and Tregs gated on CD45 cells. Results are representative of two independent experiments with 7 animals per group, and bars represent the SEM. One-way ANOVA followed by Dunnett’s test was used to determine statistical significance (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ns, not significant).

Article Snippet: Hepa1-6, a murine hepatoma cell line derived from a C57BL/6 mouse, was obtained from Japanese Collection of Research Bioresources (Osaka, Japan).

Techniques: Inhibition, Flow Cytometry

Intratumoral immune-related gene-expression changes in subcutaneous AKR tumors 7 days after the initial treatments Gene expression analyses from AKR tumors, focusing on selected mRNAs related to inflammation, lymphocytes, activation markers, exhaustion signatures, and apoptosis. C57BL/6 mice harboring subcutaneous AKR tumors were treated with intratumoral inoculations with G47Δ (5 × 10 6 PFUs) and intraperitoneal injections with an anti-CTLA-4 antibody (25 μg). The tumor tissues were harvested 7 days after the initial treatments, total RNA was extracted, cDNA was reverse transcribed, and gene expression analysis was performed using qPCR analysis. The details of the gene symbols are presented in . The fold change in expression of the indicated genes (A) with G47Δ treatment over control, (B) with CTLA-4 inhibition over control, (C) with the combination therapy over control, and (D) the combination therapy over CTLA-4 inhibition. The bar represents mean fold change + SEM (n = 6). The yellow bars represent mRNAs that were significantly upregulated (p < 0.05, fold change ≥ 2) as compared with the reference group. The blue bars show mRNAs that were significantly downregulated (p < 0.05, fold change < 0.5) as compared with the reference group. The expression data were normalized to the geometric mean of three housekeeping genes ( Actb , Gapdh , and Hprt1 ). One-way ANOVA followed by Dunnett’s test was used to determine statistical significance. All experiments were performed twice, with six samples for each group.

Journal: Molecular Therapy Oncolytics

Article Title: Oncolytic herpes virus G47Δ works synergistically with CTLA-4 inhibition via dynamic intratumoral immune modulation

doi: 10.1016/j.omto.2021.05.004

Figure Lengend Snippet: Intratumoral immune-related gene-expression changes in subcutaneous AKR tumors 7 days after the initial treatments Gene expression analyses from AKR tumors, focusing on selected mRNAs related to inflammation, lymphocytes, activation markers, exhaustion signatures, and apoptosis. C57BL/6 mice harboring subcutaneous AKR tumors were treated with intratumoral inoculations with G47Δ (5 × 10 6 PFUs) and intraperitoneal injections with an anti-CTLA-4 antibody (25 μg). The tumor tissues were harvested 7 days after the initial treatments, total RNA was extracted, cDNA was reverse transcribed, and gene expression analysis was performed using qPCR analysis. The details of the gene symbols are presented in . The fold change in expression of the indicated genes (A) with G47Δ treatment over control, (B) with CTLA-4 inhibition over control, (C) with the combination therapy over control, and (D) the combination therapy over CTLA-4 inhibition. The bar represents mean fold change + SEM (n = 6). The yellow bars represent mRNAs that were significantly upregulated (p < 0.05, fold change ≥ 2) as compared with the reference group. The blue bars show mRNAs that were significantly downregulated (p < 0.05, fold change < 0.5) as compared with the reference group. The expression data were normalized to the geometric mean of three housekeeping genes ( Actb , Gapdh , and Hprt1 ). One-way ANOVA followed by Dunnett’s test was used to determine statistical significance. All experiments were performed twice, with six samples for each group.

Article Snippet: Hepa1-6, a murine hepatoma cell line derived from a C57BL/6 mouse, was obtained from Japanese Collection of Research Bioresources (Osaka, Japan).

Techniques: Expressing, Activation Assay, Inhibition